Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Agomelatine added to Escitalopram for treatment of major depressive disorder
IRCT20130311012782N52Phase 3Completed
- Sponsor
- Shahid Sadoughi University of Medical Sciences
- Start
- Apr 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3 trial of agomelatine and escitalopram in major depressive disorder (MDD) (2 arms), sponsored by Shahid Sadoughi University of Medical Sciences. Started Apr 2021; status: completed.
02
Drugs
agomelatineescitalopram
03
Conditions
major depressive disorder (MDD)
Beyond the preview
Go deeper on IRCT20130311012782N52.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on IRCT20130311012782N52.